InvestSMART

Innate Immunotherapeutics Limited (ASX: IIL) - Announcements

Current share price for IIL : $0.360 0.02 (5.88%)+

ASX company news and announcements for Innate Immunotherapeutics Limited (IIL) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Innate Immunotherapeutics Limited (IIL) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Innate Immunotherapeutics Limited (IIL), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Innate Immunotherapeutics Limited (IIL)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
- Change of Director's Interest - Chris Collins - Placement 20 Nov 2015 11:38AM $0.200 $0.360 risen by 80%
- Placement - Section 708(A) Cleansing Statement 20 Nov 2015 10:41AM $0.200 $0.360 risen by 80%
- Appendix 3B - Placement 20 Nov 2015 10:41AM $0.200 $0.360 risen by 80%
- Appendix 4C - Quarterly Cash Flow Report Sept 15 Qtr 30 Oct 2015 11:28AM $0.180 $0.360 risen by 100%
- Results of Meeting - General Meeting to approve Placement 30 Oct 2015 11:17AM $0.180 $0.360 risen by 100%
- Notice of General Meeting/Proxy Form - Placement 25 Sep 2015 2:41PM $0.165 $0.360 risen by 118.18%
- Compassionate Use Program Update 25 Sep 2015 8:37AM $0.165 $0.360 risen by 118.18%
- Placement to Raise Additional Working Capital 21 Sep 2015 9:42AM $0.175 $0.360 risen by 105.71%
- Trading Halt 17 Sep 2015 6:48PM $0.175 $0.360 risen by 105.71%
- Initial Director's Interest Notice - Dr. Robert Peach 11 Sep 2015 12:48PM $0.165 $0.360 risen by 118.18%
- Dr. Robert Peach Appointed as a Non-Executive Director 2 Sep 2015 9:06AM $0.165 $0.360 risen by 118.18%
- Change of Director's Interest Notice - Michael Quinn 1 Sep 2015 6:32PM $0.165 $0.360 risen by 118.18%
- Results of Meeting - AGM 28 Aug 2015 12:19PM $0.180 $0.360 risen by 100%
- Chairman's Address to Shareholders - AGM 28 Aug 2015 8:32AM $0.160 $0.360 risen by 125%
- Appendix 4C - June 15 Qtr Cash Flow Report 30 Jul 2015 8:23AM $0.175 $0.360 risen by 105.71%
- Notice of Annual General Meeting/Proxy Form 24 Jul 2015 5:37PM $0.165 $0.360 risen by 118.18%
- 2015 Bioshares Investment Summit Presentation 20 Jul 2015 10:49AM $0.165 $0.360 risen by 118.18%
- Annual Report to shareholders 17 Jul 2015 8:25AM $0.160 $0.360 risen by 125%
- Full Year Statutory Accounts - Year Ended 31 March 2015 19 Jun 2015 11:59AM $0.175 $0.360 risen by 105.71%
- Preliminary Final Report - Year Ended 31 March 2015 28 May 2015 4:11PM $0.155 $0.360 risen by 132.26%
- Becoming a substantial holder - Christopher Collins 22 May 2015 2:07PM $0.155 $0.360 risen by 132.26%
- Compassionate Use Program Update 20 May 2015 8:25AM $0.155 $0.360 risen by 132.26%
- Change of Director's Interest Notice - Michael Quinn 14 May 2015 12:04PM $0.170 $0.360 risen by 111.76%
- Innate Joins MS Outcome Assessment Consortium 4 May 2015 8:27AM $0.195 $0.360 risen by 84.62%
- Appendix 4C - March 2015 Quarterly 30 Apr 2015 9:29AM $0.195 $0.360 risen by 84.62%

151 - 175 of 191 results

Page 7 of 8

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.